Abstract
A double-blind clinical trial on 60 patients with rheumatoid disease comparing 10 mg sodium aurothiomalate weekly to 50 mg weekly is continuing. An initial report on thirty of these patients, who had completed a year of treatment, shows no statistically significant difference in the response between the two groups. No conclusions can be drawn about toxic reactions in this number of patients having received treatment for only one year.